Inclusion Criteria:  Adult participants (18+years) with a former diagnoses of major depressive disorder (MDD), single or recurrent as main diagnosis confirmed by prescribing physician and currently remitted Intake of selective serotonin reuptake inhibitors (SSRI)/ serotonin-norepinephrine reuptake inhibitors (SNRI) (citalopram: 20-40mg, duloxetine: 60-100mg, escitalopram: 10-20mg, paroxetine: 20-40mg, sertraline: 50-150mg, venlafaxine: 75-150mg) or noradrenergic and specific serotonergic antidepressants (NaSSA) (mirtazapine: 30-45mg) Discontinuation wish by patient supported by prescribing physician Fulfils the criteria of the S3 national guideline recommendations "Depression" to discontinue antidepressant medication: a) response to antidepressant; b) symptom remission for at least 4 months (first episode) or for 2 years (2 or more episodes with significant functional impairment), constant intake of antidepressant medication (at least 4 weeks on a steady dose) Informed consent  Exclusion Criteria:  Current moderate or severe psychopathological symptoms or psycho-social impairments Acute or chronic somatic illness which might interfere with depressive disorder, antidepressant or proposed study Acute suicidality, psychotic symptoms, substance abuse, or addiction, current mania, or hypomania confirmed by SCID-5 or other psychopathology which might interfere with depressive disorder, antidepressant or proposed study Any history of bipolar disorder or psychosis confirmed by SCID-5 Severe stressful life events (e.g., death of a family member) within six months prior to study participation Current pregnancy Insufficient German language proficiency.